作者投稿
专家审稿
编辑办公
邮件订阅
RSS
Interpretation on the Guidelines for the Diagnosis and Treatment of Primary Osteoporosis (2022)
-
摘要: 2022年12月，《原发性骨质疏松症诊疗指南（2022）》发布，该指南更新了我国骨质疏松症的最新流行病学数据，结合该领域内的循证医学证据及临床实践经验，对骨质疏松症的诊疗作出了最新推荐。本文对指南的要点进行解读，以期为医务工作者更好地理解和遵循指南提供帮助。Abstract: In December 2022， the Guidelines for the Diagnosis and Treatment of Primary Osteoporosis (2022) were released， which updated the latest epidemiological data of osteoporosis in China， combined with evidence-based medical evidence and clinical practice experience in this field， and gave the latest recommendations for the diagnosis and treatment of osteoporosis. This article interprets the key points of the guidelines in order to help healthcare workers better understand and follow the guidelines
-
Key words:
- osteoporosis /
- epidemiological data /
- treatment /
- interpretation
-
[1] Wang O， Hu Y， Gong S， et al.A survey of outcomes and management of patients post fragility fractures in China[J]. Osteoporos Int， 2015， 26:2631-2640. [2] Hu J， Zheng W， Zhao D， et al. Health-related quality of life in men with osteoporosis: a systematic review and meta-analysis[J]. Endocrine， 2021， 74: 270-280. [3] Wang L， Yu W， Yin X， et al. Prevalence of Osteoporosis and Fracture in China: The China Osteoporosis Prevalence Study[J].JAMA Netw Open， 2021， 4:e2121106. [4] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2022)[J].中华骨质 疏松和骨矿盐疾病杂志， 2022， 15:573-611. [5] 中国疾病预防控制中心， 中华医学会骨质疏松和骨矿盐疾病分会.中国骨质疏松症流行 病学调查报告（ 2018）[M].北京： 人民卫生出版社， 2021. [6] Nayak S， Edwards DL， Saleh AA， et al. Systematic review and meta-analysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density[J]. Osteoporos Int， 2015， 26:1543-1554. [7] Kanis JA， Cooper C， Rizzoli R， et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women[J].Osteoporos Int， 2019， 30:3-44. [8] Genant HK， Wu CY， van Kuijk C， et al. Vertebral fracture assessment using a semiquantitative technique[J]. J Bone Miner Res， 1993， 8:1137-1148. [9] 中华医学会骨质疏松和骨矿盐疾病分会.骨转换生化标志物临床应用指南[J].中华骨质 疏松和骨矿盐疾病杂志， 2021， 14:321-336. [10] Camacho PM， Petak SM， Binkley N， et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE[J]. Endocr Pract， 2020， 26:1-46. [11] Wilkins Parker LR， Preuss CV. Alendronate[M]. Treasure Island (FL): StatPearls Publishing; 2023. [12] Hirota Y， Nakagawa K， Isomoto K， et al. Eldecalcitol is more effective in promoting osteogenesis than alfacalcidol in Cyp27b1-knockout mice[J].PLoS One， 2018， 13:e0199856. [13] Food and Drug Administration.Center for drug evaluation and research[EB/OL].（ 2020-11-16）[2023-08-04].https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021318Orig1s054.pdf. [14] Li N， Cornelissen D， Silverman S， et al. An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis[J]. Pharmacoeconomics， 2021， 39:181-209. [15] 李梅， 章振林， 夏维波.骨质疏松症药物治疗的必由之路:长程序贯治疗[J].中华骨质疏松 和骨矿盐疾病杂志， 2021， 14:441-446. [16] 中华医学会骨质疏松和骨矿盐疾病分会.骨质疏松性椎体压缩性骨折诊疗与管理专家共 识[J].中华骨质疏松和骨矿盐疾病杂志， 2018， 11:425-437. [17] 国务院办公厅.国务院办公厅关于推进分级诊疗制度建设的指导意见[EB/OL].（ 2015-09-08）[2023-08-04]. https://www.gov.cn/zhengce/content/2015-09/11/content_10158.htm. -
点击查看大图
计量
- 文章访问数: 173
- HTML全文浏览量: 16
- PDF下载量: 183
- 被引次数: 0
下载:
